|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
RNA interference
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2020
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:clinical_trial
|
gptkb:ORION-1
gptkb:ORION-2
gptkb:ORION-3
gptkb:ORION-4
Phase III
hyperlipidemia
|
|
gptkbp:competitors
|
gptkb:ezetimibe
statins
PCS K9 inhibitors
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to inclisiran
|
|
gptkbp:developed_by
|
gptkb:The_Medicines_Company
|
|
gptkbp:dosage_form
|
injection
|
|
gptkbp:frequency
|
twice a year
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Inclisiran
|
|
gptkbp:ingredients
|
C22 H30 N4 O6 S
|
|
gptkbp:interacts_with
|
limited drug interactions
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
C10 A X14
|
|
gptkbp:is_used_for
|
lowering LDL cholesterol
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:pharmacokinetics
|
long half-life
reduces LDL levels
|
|
gptkbp:population
|
adults with high cholesterol
patients with familial hypercholesterolemia
patients with atherosclerotic cardiovascular disease
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
gptkb:European_Society_of_Cardiology
gptkb:American_College_of_Cardiology
|
|
gptkbp:receives_funding_from
|
public and private sectors
|
|
gptkbp:research_focus
|
gptkb:hospital
cholesterol management
preventing heart attacks
preventing strokes
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
muscle pain
nausea
diarrhea
injection site reactions
|
|
gptkbp:targets
|
PCS K9 protein
|
|
gptkbp:traded_on
|
gptkb:Leqvio
|
|
gptkbp:weight
|
466.56 g/mol
|
|
gptkbp:year_created
|
gptkb:2016
|
|
gptkbp:bfsParent
|
gptkb:The_Medicines_Company
|
|
gptkbp:bfsLayer
|
6
|